Feature

Is kratom the answer to the opioid crisis?


 

Oliver Grundmann, PhD, clinical associate professor at the University of Florida, Gainesville.

Dr. Oliver Grundmann

Diagnosed with depression, the patient was introduced to kratom by a colleague who told her about kratom’s nonaddictive qualities and who had been using it to treat pain. Over 2 years, the patient became addicted to a liquid extract version of kratom and, during her rehabilitation experienced severe withdrawal symptoms, said Dr. Galbis-Reig, who was not surprised by the patient’s reaction.

“The mitragynine and 7-Hydroxymitragynine very clearly have partial opioid agonist activity with kappa antagonist activity, which is very similar to buprenorphine,” said Dr. Galbis-Reig, who is also with American Society of Addiction Medicine.

A major concern that Dr. Galbis-Reig’s case brings up is the use of liquid kratom extract.

“My biggest concern is we just don’t know what the stimulant properties of the drug are,” Dr. Galbis-Reig said. “If it turns out the properties are more in line with an amphetamine, I’m not sure that’s a great drug to use in a clinical setting for many conditions.”

Pages

Recommended Reading

Opioid deaths in the ED increase nationally
MDedge Psychiatry
Opioid prescriptions got shorter in 2017
MDedge Psychiatry
Alcohol dependence may accelerate aging, frontal cortical deficits
MDedge Psychiatry
Interventions urged to stop rising NAS, stem Medicaid costs
MDedge Psychiatry
Congress tackles the opioid epidemic. But how much will it help?
MDedge Psychiatry
FDA wants data on role of flavored tobacco products in youth initiation
MDedge Psychiatry
MDedge Daily News: Stem cells may reverse premature menopause
MDedge Psychiatry
Early family intervention tied to reduced AUDs in Mexican American youth
MDedge Psychiatry
Cannabis users at highest psychosis risk may elect to quit
MDedge Psychiatry
Parents surveyed about underage drinking
MDedge Psychiatry